ryanodine has been researched along with fasudil* in 1 studies
1 other study(ies) available for ryanodine and fasudil
Article | Year |
---|---|
Agonist-induced periodic vasomotion in rat isolated pulmonary artery.
Vasomotion is linked to the rapid oscillations of intracellular calcium levels. In rat pulmonary artery, this activity can manifest as a slow periodic on-off pattern, the timing of which depends on the type and intensity of pharmacological stimuli employed. In this study, we have sought to characterize a slow-wave vasomotor activity pattern induced in isolated arterial ring preparations by simultaneous exposure to the α(1) -adrenoceptor agonist phenylephrine (1-10 nm) and the L channel agonist S(-)-Bay K 8644 (3-20 nm). Treated tissues responded with a stable on-off pattern of vasomotion persisting for >5 h at 5-6 cycles/h. In intact rings, this response was suppressed by methacholine and restored or enhanced by N(ω) -nitro-l-arginine methyl ester. Analogous inhibitory effects were obtained with high Mg(2+) , 8-Br-cGMP (but not 8-Br-cAMP), riluzole, ryanodine, chelerythrine, and fasudil. Pinacidil (30 nm) increased off-cycle length without change in slow-wave amplitude. Conversely, tetraethylammonium (1.0-3.0 mm) augmented the latter without affecting periodicity. Carbenoxolone (10 μm) abolished slow-wave activity, while raising basal tone and inducing random phasic activity. In endothelium-denuded rings, the threshold of agonist-induced slow-wave vasomotion was lowered and a similar inhibitory effect obtained with carbenoxolone. In conclusion, the slow-wave pattern of vasomotion described here is (i) subject to inhibitory modulation by endothelial NO and an array of voltage-gated and leak K conductances yet to be fully characterized; (ii) dependent on Ca(2+) from both extracellular and sarcoendoplasmatic sources; (iii) controlled by kinase (Rho and PKC)-mediated regulation of myosin light chain phosphatase; and (iv) synchronized via intermyocyte gap junctions. Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; 8-Bromo Cyclic Adenosine Monophosphate; Adrenergic alpha-1 Receptor Agonists; Animals; Benzophenanthridines; Calcium Channel Agonists; Calcium Signaling; Carbenoxolone; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Endothelium, Vascular; Gap Junctions; In Vitro Techniques; Male; Methacholine Chloride; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Phenylephrine; Pinacidil; Potassium Channels; Protein Kinase C; Protein Kinase Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Riluzole; Ryanodine; Tetraethylammonium; Vasomotor System | 2011 |